Literature DB >> 19036526

Could glial activation be a factor in migraine?

Jim Bartley1.   

Abstract

Migraine represents a central neural hypersensitivity. During an attack, migraine sufferers can be hypersensitive to normal levels of sound, light, smell and movement. Sensory processing dysfunction in the brain stem or diencephalic nuclei has been implicated. Most scientific migraine research has focused on neuronal function because of their central role in the processing, integration and transmission of sensory information. However the supporting glia, their receptors and their secreted mediators are now recognised as having an important role in neuronal function regulation. Activated microglia and astrocytes produce and release a variety of neuroexcitatory substances including nitric oxide, excitatory amino acids and proinflammatory cytokines. Spinal glial activation and the subsequent release of proinflammatory mediators initiate and maintain a range of enhanced pain states. The focus on neuronal function has ignored the potential contribution of glial cell activation to neural hypersensitivity and pain. If the central neuronal hypersensitivity associated with migraine represents glial cell activation, drugs that block glial cell activation and the subsequent release of neuroexcitatory substances could have therapeutic potential in both acute migraine treatment and migraine prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036526     DOI: 10.1016/j.mehy.2008.09.048

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  16 in total

Review 1.  Why do migraines often decrease as we age?

Authors:  Frederick G Freitag
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 2.  The bowel and migraine: update on celiac disease and irritable bowel syndrome.

Authors:  Roger K Cady; Kathleen Farmer; J Kent Dexter; Jessica Hall
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 3.  Meeting acute migraine treatment needs through novel treatment formulations.

Authors:  Stephen D Silberstein
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

4.  Tetrandrine Alleviates Nociception in a Rat Model of Migraine via Suppressing S100B and p-ERK Activation in Satellite Glial Cells of the Trigeminal Ganglia.

Authors:  Guangcheng Qin; Bei Gui; Jingmei Xie; Lixue Chen; Lianlian Chen; Zhiwei Cui; Jiying Zhou; Ge Tan
Journal:  J Mol Neurosci       Date:  2017-11-16       Impact factor: 3.444

Review 5.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

6.  Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats.

Authors:  Nagla Ahmed El-Nabarawy; Mahmoud Hassan Teaima; Doaa Ahmed Helal
Journal:  Drug Des Devel Ther       Date:  2019-11-21       Impact factor: 4.162

7.  Vitamin D Deficiency and Pain: Clinical Evidence of Low Levels of Vitamin D and Supplementation in Chronic Pain States.

Authors:  Elspeth E Shipton; Edward A Shipton
Journal:  Pain Ther       Date:  2015-04-29

8.  α6GABAA Receptor Positive Modulators Alleviate Migraine-like Grimaces in Mice via Compensating GABAergic Deficits in Trigeminal Ganglia.

Authors:  Hung-Ruei Tzeng; Ming Tatt Lee; Pi-Chuan Fan; Daniel E Knutson; Tzu-Hsuan Lai; Werner Sieghart; James Cook; Lih-Chu Chiou
Journal:  Neurotherapeutics       Date:  2020-10-27       Impact factor: 7.620

Review 9.  Glia and Orofacial Pain: Progress and Future Directions.

Authors:  Yi Ye; Elizabeth Salvo; Marcela Romero-Reyes; Simon Akerman; Emi Shimizu; Yoshifumi Kobayashi; Benoit Michot; Jennifer Gibbs
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

10.  A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine.

Authors:  Yuen H Kwok; James E Swift; Parisa Gazerani; Paul Rolan
Journal:  J Pain Res       Date:  2016-10-31       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.